1: Spiridigliozzi GA, Hart SJ, Heller JH, Schneider HE, Baker JA, Weadon C, 
Capone GT, Kishnani PS. Safety and efficacy of rivastigmine in children with Down 
syndrome: A double blind placebo controlled trial. Am J Med Genet A. 2016 Apr 8. 
doi: 10.1002/ajmg.a.37650. [Epub ahead of print] PubMed PMID: 27061338.

2: Nieto RA, Deardorff WJ, Grossberg GT. Efficacy of rivastigmine tartrate, 
transdermal system, in Alzheimer's disease. Expert Opin Pharmacother. 2016 
Apr;17(6):861-70. doi: 10.1517/14656566.2016.1159296. PubMed PMID: 26918774.

3: Mohamed LA, Keller JN, Kaddoumi A. Role of P-glycoprotein in mediating 
rivastigmine effect on amyloid-β brain load and related pathology in Alzheimer's 
disease mouse model. Biochim Biophys Acta. 2016 Apr;1862(4):778-87. doi: 
10.1016/j.bbadis.2016.01.013. Epub 2016 Jan 15. PubMed PMID: 26780497; PubMed 
Central PMCID: PMC4788561.

4: Papp M, Gruca P, Lason-Tyburkiewicz M, Willner P. Antidepressant, anxiolytic 
and procognitive effects of rivastigmine and donepezil in the chronic mild stress 
model in rats. Psychopharmacology (Berl). 2016 Apr;233(7):1235-43. doi: 
10.1007/s00213-016-4206-0. Epub 2016 Jan 15. PubMed PMID: 26769042; PubMed 
Central PMCID: PMC4801996.

5: Zhang ZX, Hong Z, Wang YP, He L, Wang N, Zhao ZX, Zhao G, Shang L, Weisskopf 
M, Callegari F, Strohmaier C. Rivastigmine Patch in Chinese Patients with 
Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group 
Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily). 
CNS Neurosci Ther. 2016 Mar 25. doi: 10.1111/cns.12521. [Epub ahead of print] 
PubMed PMID: 27012596.

6: Bokde AL, Cavedo E, Lopez-Bayo P, Lista S, Meindl T, Born C, Galluzzi S, 
Faltraco F, Dubois B, Teipel SJ, Reiser M, Möller HJ, Hampel H. Effects of 
rivastigmine on visual attention in subjects with amnestic mild cognitive 
impairment: A serial functional MRI activation pilot-study. Psychiatry Res. 2016 
Mar 30;249:84-90. doi: 10.1016/j.pscychresns.2016.01.018. Epub 2016 Jan 18. 
PubMed PMID: 26851974.

7: Simon A, Amaro MI, Cabral LM, Healy AM, de Sousa VP. Development of a novel 
dry powder inhalation formulation for the delivery of rivastigmine hydrogen 
tartrate. Int J Pharm. 2016 Mar 30;501(1-2):124-38. doi: 
10.1016/j.ijpharm.2016.01.066. Epub 2016 Feb 1. PubMed PMID: 26836711.

8: Henderson EJ, Lord SR, Brodie MA, Gaunt DM, Lawrence AD, Close JC, Whone AL, 
Ben-Shlomo Y. Rivastigmine for gait stability in patients with Parkinson's 
disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. 
Lancet Neurol. 2016 Mar;15(3):249-58. doi: 10.1016/S1474-4422(15)00389-0. Epub 
2016 Jan 13. PubMed PMID: 26795874.

9: Higashino K, Ago Y, Umeki T, Hasebe S, Onaka Y, Hashimoto H, Takuma K, Matsuda 
T. Rivastigmine improves isolation rearing-induced prepulse inhibition deficits 
via muscarinic acetylcholine receptors in mice. Psychopharmacology (Berl). 2016 
Feb;233(3):521-8. doi: 10.1007/s00213-015-4123-7. Epub 2015 Oct 31. PubMed PMID: 
26518025.

10: Imbernón-Moya A, Podlipnik S, Burgos F, Vargas-Laguna E, Aguilar-Martínez A, 
Fernández-Cogolludo E, Gallego-Valdes MA. Acquired Localized Hypertrichosis 
Induced by Rivastigmine. Case Rep Dermatol Med. 2016;2016:7296572. doi: 
10.1155/2016/7296572. Epub 2016 Mar 17. PubMed PMID: 27073702; PubMed Central 
PMCID: PMC4814665.

11: Bezerra da Silva C, Pott A, Elifio-Esposito S, Dalarmi L, Fialho do 
Nascimento K, Moura Burci L, de Oliveira M, de Fátima Gaspari Dias J, Maria 
Warumby Zanin S, Gomes Miguel O, Dallarmi Miguel M. Effect of Donepezil, Tacrine, 
Galantamine and Rivastigmine on Acetylcholinesterase Inhibition in Dugesia 
tigrina. Molecules. 2016 Jan 11;21(1). pii: E53. doi: 10.3390/molecules21010053. 
PubMed PMID: 26760993.

12: Soysal P, Isik AT. Asymptomatic Bradycardia Due to Rivastigmine in an Elderly 
Adult with Lewy Body Dementia. J Am Geriatr Soc. 2015 Dec;63(12):2648-2650. doi: 
10.1111/jgs.13858. PubMed PMID: 26691714.

13: Shah B, Khunt D, Bhatt H, Misra M, Padh H. Application of quality by design 
approach for intranasal delivery of rivastigmine loaded solid lipid 
nanoparticles: Effect on formulation and characterization parameters. Eur J Pharm 
Sci. 2015 Oct 12;78:54-66. doi: 10.1016/j.ejps.2015.07.002. Epub 2015 Jul 2. 
PubMed PMID: 26143262.

14: van Schaik AM, Rhebergen D, Henstra MJ, Kadouch DJ, van Exel E, Stek ML. 
Cognitive Impairment and Electroconvulsive Therapy in Geriatric Depression, What 
Could be the Role of Rivastigmine? A Case Series. Clin Pract. 2015 Sep 
28;5(3):780. doi: 10.4081/cp.2015.780. eCollection 2015 Sep 28. PubMed PMID: 
26664715; PubMed Central PMCID: PMC4653751.

15: Nakamura Y, Strohmaier C, Tamura K, Kataoka N, Nakano M, Oda S, Nishimura K, 
Homma A. A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, 
Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in 
Japanese Patients with Mild to Moderate Alzheimer's Disease. Dement Geriatr Cogn 
Dis Extra. 2015 Sep 29;5(3):361-74. doi: 10.1159/000439269. eCollection 2015 
Sep-Dec. PubMed PMID: 26557135; PubMed Central PMCID: PMC4637522.

16: Birks JS, Chong LY, Grimley Evans J. Rivastigmine for Alzheimer's disease. 
Cochrane Database Syst Rev. 2015 Sep 22;9:CD001191. [Epub ahead of print] Review. 
PubMed PMID: 26393402.

17: Isaacson RS, Ferris S, Velting DM, Meng X. Cognitive Efficacy (SIB) of 13.3 
Versus 4.6 mg/24 h Rivastigmine Patch in Severe Alzheimer's Disease. Am J 
Alzheimers Dis Other Demen. 2015 Sep 14. pii: 1533317515603687. [Epub ahead of 
print] PubMed PMID: 26371345.

18: D'Onofrio G, Sancarlo D, Addante F, Ciccone F, Cascavilla L, Paris F, Elia 
AC, Nuzzaci C, Picoco M, Greco A, Panza F, Pilotto A. A pilot randomized 
controlled trial evaluating an integrated treatment of rivastigmine transdermal 
patch and cognitive stimulation in patients with Alzheimer's disease. Int J 
Geriatr Psychiatry. 2015 Sep;30(9):965-75. doi: 10.1002/gps.4247. Epub 2014 Dec 
12. PubMed PMID: 25504466.

19: Diaz MC, Rosales RL. A Case Report on Dyskinesia Following Rivastigmine Patch 
13.3 mg/24 hours for Alzheimer's Disease: Perspective in the Movement Disorders 
Spectrum Following Use of Cholinesterase Inhibitors. Medicine (Baltimore). 2015 
Aug;94(34):e1364. doi: 10.1097/MD.0000000000001364. PubMed PMID: 26313774; PubMed 
Central PMCID: PMC4602930.

20: Zamani M, Mohammadi M, Zamani H, Tavasoli A. Pharmacogenetic Study on the 
Impact of Rivastigmine Concerning Genetic Variants of A2M and IL-6 Genes on 
Iranian Alzheimer's Patients. Mol Neurobiol. 2015 Aug 21. [Epub ahead of print] 
PubMed PMID: 26289409.